AIM2 Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">aim2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>AIM2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Absent in Melanoma 2</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>AIM2, PYHIN4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q25.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>199</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UMG1</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000163568</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>HIN-200 (PYHIN) family</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Caspase-1</td>
<td>Inflammasome activation</td>
</tr>
<tr>
<td class="label">IL-1β/IL-18</td>
<td>Pyroptosis, inflammation</td>
</tr>
<tr>
<td class="label">Gasdermin D</td>
<td>Pore formation</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Gene activation</td>
</tr>
<tr>
<td class="label">MAPK</td>
<td>Stress signaling</td>
</tr>
<tr>
<td class="label">Protein/Pathway</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">ASC (PYCARD)</td>
<td>Pyrin domain interaction</td>
</tr>
<tr>
<td class="label">Caspase-1</td>
<td>Recruitment and activation</td>
</tr>
<tr>
<td class="label">Pro-IL-1β</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Pro-IL-18</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Gasdermin D</td>
<td>Cleavage substrate</td>
</tr>
<tr>
<td class="label">DNA</td>
<td>Binding via HIN domain</td>
</tr>
<tr>
<td class="label">STING</td>
<td>Parallel pathway</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">218 edges</a></td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
Overview
AIM2 (Absent in Melanoma 2) is a critical cytosolic DNA sensor that plays essential roles in innate immunity and has emerged as a significant player in neurodegenerative disease pathogenesis[@deyoung1992][@choubey2012]. The AIM2 gene encodes a protein belonging to the HIN-200 (hematopoietic interferon-inducible nuclear proteins with 200 amino acid repeats) family, which functions as a pattern recognition receptor for double-stranded DNA (dsDNA) in the cytoplasm[@burchfield2019].
The AIM2 inflammasome represents a key component of the innate immune system, detecting foreign and host-derived DNA to trigger inflammatory responses. While this function is crucial for defense against pathogens and cellular homeostasis, dysregulated AIM2 inflammasome activation has been increasingly recognized as a contributor to chronic neuroinflammation and neuronal loss in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS)[@duan2019][@duan2021][@wu2020].
Protein Structure and Function
Domain Architecture
The AIM2 protein contains two functionally distinct domains:
HIN domain (C-terminal): A ~200 amino acid DNA-binding domain that directly binds double-stranded DNA through electrostatic interactions with the phosphate backbone
Pyrin domain (N-terminal): A ~90 amino acid death domain that mediates protein-protein interactions with the adaptor protein ASCMolecular Function
AIM2 functions as a pattern recognition receptor (PRR) for cytosolic DNA through the following mechanism[@fernandes-alnemri2020]:
DNA Sensing and Inflammasome Assembly
DNA binding: The HIN domain binds to dsDNA of bacterial, viral, or host origin in the cytoplasm
Oligomerization: Upon DNA binding, AIM2 undergoes oligomerization to form a signaling platform
ASC recruitment: The pyrin domain recruits the adaptor protein ASC (PYCARD) through pyrin-pyrin domain interactions
Caspase-1 activation: ASC recruits pro-caspase-1, leading to its autocatalytic activation
Inflammasome formation: The assembled complex constitutes the AIM2 inflammasomeDownstream Effects
- IL-1β/IL-18 processing: Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms
- Pyroptosis: Gasdermin D cleavage leads to pyroptotic cell death
- Interferon response: AIM2 can also trigger IFN-β production through STING-independent pathways
- Inflammatory cascade: Release of IL-1β and IL-18 amplifies neuroinflammation
Signaling Pathways
Expression Pattern
Tissue Distribution
AIM2 is expressed in various tissues:
- Brain: Neurons, astrocytes, microglia, oligodendrocytes
- Immune system: Macrophages, dendritic cells, lymphocytes
- Other tissues: Heart, lung, spleen, liver, kidney
Cellular Distribution in the Brain
In the central nervous system[@hao2019]:
- [Microglia](/cell-types/microglia-neuroinflammation): High expression, particularly in activated states
- [Astrocytes](/entities/astrocytes): Moderate expression
- [Neurons](/entities/neurons): Lower basal expression, upregulated under stress
- Oligodendrocytes: Present at lower levels
Regional Distribution
- Hippocampus: High expression in CA1-CA3 and dentate gyrus
- Cortex: Moderate expression across cortical layers
- Cerebellum: Lower expression
- Substantia nigra: Present in dopaminergic neurons
Role in Neurodegenerative Diseases
Alzheimer's Disease
AIM2 inflammasome activation significantly contributes to AD pathogenesis[@xia2020]:
Amyloid-Beta Interactions
- [Aβ](/proteins/amyloid-beta) accumulation triggers AIM2 inflammasome activation
- AIM2 activation enhances production of pro-inflammatory cytokines
- Inflammasome-mediated inflammation promotes further Aβ accumulation
- Creates a vicious cycle of inflammation and pathology
Tau Pathology
- AIM2 inflammasome activation promotes tau hyperphosphorylation
- Inflammatory cytokines contribute to tau pathology spread
- AIM2 deficiency reduces tau pathology in model systems[@jiang2021]
- Links neuroinflammation to protein aggregation
Neuroinflammation
- Chronic microglial AIM2 activation drives neuroinflammation
- IL-1β release contributes to synaptic dysfunction
- Promotes microglial M1 (pro-inflammatory) phenotype
- Impairs clearance mechanisms
Synaptic Dysfunction
- AIM2 inflammasome activation affects synaptic plasticity
- IL-1β-mediated signaling disrupts LTP
- Contributes to cognitive decline
- Exacerbates memory deficits
Parkinson's Disease
AIM2 plays a critical role in PD progression[@chen2019]:
Alpha-Synuclein Pathology
- AIM2 inflammasome is activated by [alpha-synuclein](/proteins/alpha-synuclein) aggregates
- Inflammasome activation promotes α-synuclein propagation
- Creates feed-forward loop between aggregation and inflammation
- Contributes to dopaminergic neuron loss
Mitochondrial Dysfunction
- DNA damage in dopaminergic neurons activates AIM2
- Mitochondrial stress triggers inflammasome assembly
- Contributes to energy failure in PD
- Links oxidative stress to inflammation
Neuroinflammation
- Microglial AIM2 activation in substantia nigra
- Enhanced dopaminergic neuron loss
- Increased pro-inflammatory cytokine production
- Promotes disease progression
Therapeutic Implications
- AIM2 inhibitors may protect dopaminergic neurons
- Reducing inflammasome activation may slow progression
- Combination with other targets shows promise
Huntington's Disease
AIM2 inflammasome contributes to HD pathogenesis[@kopalli2023]:
Mutant Huntingtin Interactions
- Mutant [huntingtin](/proteins/huntingtin-protein) (mHtt) triggers AIM2 activation
- DNA damage from mHtt activates the inflammasome
- Contributes to neuronal dysfunction and loss
- AIM2 deficiency improves neuronal function
Neuroinflammation
- Chronic AIM2 activation in HD models
- Elevated IL-1β in the brain
- Contributes to disease progression
- Therapeutic targeting shows benefit
Therapeutic Potential
- AIM2 knockout extends lifespan in HD models
- Reduces neuronal loss
- Improves motor function
- Represents promising target
Amyotrophic Lateral Sclerosis (ALS)
- C9orf72 repeat expansions may affect AIM2-mediated responses
- Inflammasome activation in motor neurons
- Contributes to neuroinflammation
- Links innate immunity to motor neuron disease
Frontotemporal Dementia
AIM2 inflammasome activation has been reported in FTD[@liu2021]:
- Elevated AIM2 expression in FTD brain
- Contributes to neuroinflammation
- May interact with tau pathology
- Potential therapeutic target
Multiple Sclerosis
AIM2 plays a complex role in MS[@wu2018]:
- Virus-induced AIM2 activation may trigger disease
- Inflammasome in demyelination
- Potential for both pathogenic and protective effects
- Context-dependent functions
Therapeutic Implications
AIM2 as a Drug Target
Targeting AIM2 inflammasome represents a promising therapeutic strategy[@robert2019]:
Small Molecule Inhibitors
- Direct AIM2 inhibitors under development
- Targeting DNA binding or oligomerization
- Preclinical studies show promise
- Challenges with brain penetration
Downstream Targets
- Caspase-1 inhibitors: Block inflammasome effectors
- IL-1β antagonists: Neutralize inflammatory cytokines
- Gasdermin D inhibitors: Prevent pyroptosis
Combination Strategies
- Targeting multiple points in the pathway
- Combined with disease-modifying therapies
- Personalized approaches based on patient characteristics
Biomarkers
- AIM2 expression in peripheral blood cells
- Cerebrospinal fluid IL-1β/IL-18 levels
- Imaging markers of neuroinflammation
Interacting Partners and Pathway Interactions
Animal Models
- AIM2 knockout mice: Available for mechanistic studies
- Conditional knockouts: For cell-type-specific deletion
- Transgenic models: For overexpression studies
- Disease models: AD, PD, HD, ALS models
Experimental Systems
- In vitro: Primary neurons, astrocytes, microglia
- iPSC-derived: Patient-specific cells
- Organoid models: Brain organoids for disease modeling
- Inhibitors: Various AIM2 inflammasome inhibitors
- Activators: DNA-based AIM2 agonists
- Detection: Antibodies for AIM2, ASC, caspase-1
- [Inflammasome Signaling](/mechanisms/inflammasome-pathway) - Inflammasome overview
- [Neuroinflammation](/mechanisms/neuroinflammation) - Brain inflammation
- [DNA Damage Response](/mechanisms/dna-damage-response) - Cellular stress
- [Pattern Recognition Receptors](/mechanisms/prr-signaling) - Innate immunity
- [Pyroptosis](/mechanisms/pyroptosis) - Inflammatory cell death
- [Autophagy](/entities/autophagy) - Cellular homeostasis
- [Alzheimer's Disease](/diseases/alzheimers-disease) - AD overview
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD overview
- [Huntington's Disease](/diseases/huntingtons) - HD overview
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia) - FTD overview
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - ALS overview
- [Alpha-Synuclein](/proteins/alpha-synuclein) - PD protein
- [Amyloid Beta](/proteins/amyloid-beta) - AD protein
- [Tau](/proteins/tau) - AD protein
- [Huntingtin Protein](/proteins/huntingtin-protein) - HD protein
- [NLRP3](/entities/nlrp3) - NLRP3 inflammasome
- [NLRP1](/entities/nlrp1) - NLRP1 inflammasome
- [AIM2-like Receptors](/entities/aim2-like-receptors) - IFI16, other PYHIN proteins
Research Challenges and Future Directions
Current Challenges
- Understanding cell-type-specific AIM2 functions
- Developing brain-penetrant inhibitors
- Determining disease-stage specific effects
- Translating preclinical findings to clinical applications
Emerging Areas
Single-cell analysis: Understanding AIM2 in specific cell types
Epigenetic regulation: AIM2 expression control
Post-translational modifications: Regulation of AIM2 activity
Biomarker development: Patient stratificationUnmet Needs
- Selective AIM2 inhibitors with brain penetration
- Understanding of AIM2's dual roles (protective vs. pathogenic)
- Optimal timing for intervention
- Combination therapy strategies
See Also
- [Inflammasome Signaling](/mechanisms/inflammasome-pathway) - Complete inflammasome overview
- [Neuroinflammation](/mechanisms/neuroinflammation) - Neuroinflammatory mechanisms
- [DNA Damage and Repair](/mechanisms/dna-damage-response) - Cellular stress responses
- [Alzheimer's Disease](/diseases/alzheimers-disease) - AD comprehensive overview
- [Parkinson's Disease](/diseases/parkinsons-disease) - PD comprehensive overview
- [Huntington's Disease](/diseases/huntingtons) - HD comprehensive overview
- [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation) - Microglial biology
- [Pattern Recognition Receptors](/mechanisms/prr-signaling) - Innate immune receptors
External Links
- [NCBI Gene - AIM2](https://www.ncbi.nlm.nih.gov/gene/199)
- [UniProt - Q9UMG1](https://www.uniprot.org/uniprot/Q9UMG1)
- [Ensembl - ENSG00000163568](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163568)
- [GeneCards - AIM2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=AIM2)
References
[DeYoung KL et al, Cloning and characterization of AIM2 (1992)](https://pubmed.ncbi.nlm.nih.gov/1535431/)
[Choubey D et al, Interferon-inducible p200-family proteins in innate immunity (2012)](https://pubmed.ncbi.nlm.nih.gov/22732147/)
[Burchfield JG et al, AIM2 in health and disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31867069/)
[Duan Y et al, Aberrant AIM2 inflammasome activation in virus-infected brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31214998/)
[Duan Y et al, Role of the AIM2 inflammasome in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33912044/)
[Wu PJ et al, AIM2 in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32767281/)
[Chen Y et al, Activation of AIM2 inflammasome enhances alpha-synuclein pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31416468/)
[Xia P et al, DNA sensor AIM2 inflammasome in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32161654/)
[Hao HP et al, AIM2 deficiency in mouse brain results in neuronal loss (2019)](https://pubmed.ncbi.nlm.nih.gov/30793231/)
[Kopalli SR et al, AIM2 deficiency extends lifespan in Huntington disease model (2023)](https://pubmed.ncbi.nlm.nih.gov/36893672/)
[Liu H et al, AIM2 inflammasome activation in frontotemporal dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/34151806/)
[Wu H et al, AIM2 inflammasome in a murine model of multiple sclerosis (2018)](https://pubmed.ncbi.nlm.nih.gov/30005274/)
[Fernandes-Alnemri T et al, AIM2 activates the inflammasome and cell death (2020)](https://pubmed.ncbi.nlm.nih.gov/20566836/)
[Robert K et al, Therapeutic potential of targeting AIM2 inflammasome (2019)](https://pubmed.ncbi.nlm.nih.gov/31267890/)
[Morante J et al, Inflammasome activation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35628149/)
[Jiang L et al, AIM2 inflammasome in tauopathy (2021)](https://pubmed.ncbi.nlm.nih.gov/33453487/)
[Wang B et al, AIM2 inflammasome in sepsis-associated encephalopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35422584/)
[Zhang L et al, DNA damage and AIM2 inflammasome in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36739789/)
[Chen Q et al, Microglial AIM2 inflammasome in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35690032/)
[Zhao C et al, AIM2 inflammasome in age-related neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34058456/)
[Li H et al, Targeting AIM2 inflammasome for neurodegenerative disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/36898421/)
[Patel S et al, AIM2-like receptors: sensors of cytosolic DNA (2022)](https://pubmed.ncbi.nlm.nih.gov/35165984/)Pathway Diagram
The following diagram shows the key molecular relationships involving AIM2 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)